Cocrystal Pharma

Cocrystal Pharma, Inc. is a biotechnology company, which engages in the discovery and development of novel antiviral therapeutics. It focuses on the preclinical and early clinical stage antiviral compounds for unmet medical needs including influenza, Hepatitis C virus, and norovirus infections. The company was founded in 2008 and is headquartered in Bothell, WA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BOTHELL, Wash., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces it has engaged hVIVO, a subsidiary of London-based Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organization (CRO), to conduct a Phase 2a clinical trial with the Company's novel, broad-spectrum, orally administered antiviral candidate CC- 42344. This candidate represents a new class of investigational medicine designed to directly inhibit replication of the virus for the treatment of pandemic and seasonal influenza A.

Cocrystal Pharma Engages CRO to Conduct Phase 2a Human Challenge Influenza A Clinical Trial with Novel, Broad-Spectrum Antiviral Candidate CC-42344

Phoenix, Arizona--(Newsfile Corp. - August 3, 2022) - The Stock Day Podcast welcomed Cocrystal Pharma, Inc. (NASDAQ: COCP) ("the Company"), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), hepatitis C viruses and noroviruses. CFO and co-interim CEO James (Jim) Martin joined Stock Day host Sever Copley. Copley began the interview by asking about the Company's platform and influenza therapies.

Cocrystal Pharma Discusses Therapeutic Platform Applications and Progress with The Stock Day Podcast

BOTHELL, Wash., May 18, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that James Martin, Chief Financial Officer and co-interim Chief Executive Officer, will present a Company overview at the H.C. Wainwright Global Investment Conference on Wednesday, May 25, 2022 at 10:00 a.m. Eastern Time. The hybrid in-person and virtual conference is being held at the Fontainebleau Miami Beach Hotel in Miami Beach.

Cocrystal Pharma to Present at the H.C. Wainwright Global Investment Conference

BOTHELL, Wash., May 11, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) reports financial results for the three months ended March 31, 2022, and provides updates on its antiviral pipeline, upcoming milestones and business activities.

Cocrystal Pharma Reports First Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs and Milestones

BOTHELL, Wash., April 19, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that Sam Lee, PhD, President and co-interim Chief Executive Officer, will present a Company overview at the hybrid in-person and virtual Life Science Innovation Northwest 2022 (LSINW) Conference being held April 20-21, 2022 at the Washington State Convention Center in Seattle. Dr. Lee's presentation is scheduled during the Neuroscience & Pharmaceuticals segment on Wednesday, April 20 at 3:25 p.m. Pacific time.

Cocrystal Pharma to Present at the Life Science Innovation Northwest 2022 Conference

Cocrystal Pharma Inc (NASDAQ: COCP) reported preliminary results of a Phase 1 study with CC-42344, a broad-spectrum oral antiviral to treat pandemic and seasonal influenza A. The ongoing Phase 1 trial, designed to evaluate CC-42344 administered in single-ascending and multiple-.

Cocrystal Pharma Posts Favorable Preliminary Data From Influenza A Antiviral Candidate Trial

CC-42344 administered orally as a single 100 mg or 200 mg dose in healthy adults showed a favorable safety and pharmacokinetic profile

Cocrystal Pharma Reports Favorable Preliminary Data from Phase 1 Initial Cohorts with CC-42344, a Novel, Broad-Spectrum Influenza A antiviral

BOTHELL, Wash., March 23, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) reports financial results for the 12 months ended December 31, 2021, and provides updates on its antiviral pipeline, upcoming milestones and business activities.

Cocrystal Pharma Reports 2021 Financial Results and Provides Updates on Development Programs and Milestones

BOTHELL, Wash., March 22, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that management will participate in the 2022 Virtual Growth Conference, presented by Maxim Group and hosted by M-Vest, being held March 28-30, 2022. Those interested in attending the virtual conference can register here .

Cocrystal Pharma to Participate in the Maxim Group 2022 Virtual Growth Conference

BOTHELL, Wash., March 10, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces dosing of the first subjects in a Phase 1 clinical trial of healthy adults evaluating its novel, broad-spectrum, orally administered antiviral CC-42344 for the treatment of pandemic and seasonal influenza A. The study is designed to assess the safety, tolerability and pharmacokinetics of CC-42344 with results expected later this year.

Cocrystal Pharma Initiates Enrollment in Phase 1 Influenza A Study with Novel, Broad-Spectrum, Orally Administrated Antiviral CC-42344

CDI-988 and CDI-873 target a highly conserved region in the active site of SARS-CoV-2 main (3CL) protease required for viral RNA replication.

Cocrystal Pharma To Develop Additional Two Antiviral Drug Candidates For COVID-19

Novel broad-spectrum oral lead candidates CDI-988 and CDI- 873 , discovered using Cocrystal's antiviral drug discovery platform , demonstrate superior in vitro potency against SARS-CoV-2 and activity against all variants of concern including Omicron

Cocrystal Pharma Selects Two Lead Antiviral Drug Candidates for its COVID-19 Oral Drug Program

Response to pre-IND briefing package supports pathway to initiating a Phase 1 clinical study in 2022

Cocrystal Pharma Receives FDA Guidance to Advance Clinical Development of its COVID-19 Antiviral CDI-45205

Cocrystal Pharma Inc's (NASDAQ: COCP) COVID-19 antiviral candidate has shown antiviral potency against the omicron variant in vitro studies.  The Company earlier confirmed that its protease inhibitors demonstrated broad-spectrum antiviral activity against SARS-CoV-2 and all major previously identified variants, including Delta, Alpha, Beta, and Gamma.

Cocrystal's COVID-19 Antiviral Candidate Shows Potency Against Omicron Variant

Antiviral activity now confirmed against SARS-CoV-2 and all variants of concern including Omicron, Delta, Alpha, Beta and Gamma

Cocrystal Pharma's COVID-19 Oral and Intranasal/Pulmonary Protease Inhibitors Exhibit Powerful In Vitro Potency Against the SARS-CoV-2 Omicron Variant

CTI BioPharma

Eton Pharmaceuticals Inc

ObsEva

These biotech penny stocks could be worth watching after recent announcements The post 4 Biotech Penny Stocks to Watch With New Catalysts appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Biotech Penny Stocks to Watch With New Catalysts

BOTHELL, Wash., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that President and interim CEO Sam Lee, Ph.D. and CFO and interim CEO James Martin will present a company overview in the Noble Capital Markets Virtual Roadshow Series presented by Channelchek. The live presentation will be by webcast on Wednesday, December 8, 2021 at 1:00 p.m. Eastern time (10:00 a.m. Pacific time). Registration for the webcast presentation is available here.

Cocrystal Pharma to Discuss Progress with COVID-19 Antiviral Programs and Clinical Strategy During Noble Capital Markets' Channelchek Virtual Roadshow

Unveils designs for Phase 1 and 2 stud ies with intranasal/pulmonary and oral SARS-CoV-2 protease inhibitors ; trial initiations expected in 2022

Cocrystal Pharma Presents Preclinical Data from COVID-19 Antiviral Programs and Outlines Near-Term Clinical Plans at the World Antiviral Congress 2021

Cocrystal Pharma, Inc. (COCP) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Cocrystal Pharma, Inc. (COCP) Reports Q3 Loss, Lags Revenue Estimates

Cocrystal Pharma, Inc. (COCP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Cocrystal Pharma, Inc. (COCP) Report Negative Q3 Earnings? What You Should Know

BOTHELL, Wash., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc.  (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that its SARS-CoV-2 main protease inhibitors showed potent in vitro pan-viral activity against human common coronaviruses, rhinoviruses, and respiratory enteroviruses that frequently cause the common cold, as well as against noroviruses that can cause symptoms of acute gastroenteritis. These protease inhibitors were discovered using the company's proprietary structure-based drug discovery technology and are currently being advanced by Cocrystal toward clinical development to combat SARS-CoV-2 and its variants.

Cocrystal Pharma's SARS-CoV-2 Main Protease Inhibitors Demonstrate Pan-viral Activity against Human Common Coronaviruses, Noroviruses, Rhinoviruses, and Enteroviruses

Cocrystal Pharma Inc (NASDAQ: COCP) has submitted a pre-Investigational New Drug (IND) briefing package to the FDA for its broad-spectrum protease inhibitor CDI-45205 in COVID-19. FDA's response is expected to provide greater clarity and guidance on designing Phase 1 and Phase 2 trials for CDI-45205.

Cocrystal Pharma Files To Start Human Trial For Protease Inhibitor In COVID-19

FDA 's response is expected to provide greater clarity and guidance on designing Phase 1 and Phase 2 clinical trials for CDI-45205

Cocrystal Pharma Submits Pre-Investigational New Drug Briefing Package to the FDA for Clinical Development Guidance of CDI-45205 for COVID-19 Treatment

BOTHELL, Wash., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc.  (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of coronaviruses, influenza, hepatitis C viruses and noroviruses, announces that management will present at the Dawson James 2021 Small Cap Growth Conference on Thursday, October 21, 2021 at 2:00 p.m. Eastern time (10:00 a.m. Pacific time). The conference is being held at the Wyndham Grand Hotel in Jupiter, Fla.

Cocrystal Pharma to Present at the Dawson James 2021 Small Cap Growth Conference on October 21, 2021

BOTHELL, Wash., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of coronaviruses, influenza, hepatitis C viruses and noroviruses, announces receipt of clearance from an Australian Human Research Ethics Committee (HREC) to initiate a Phase 1 trial with its orally administered PB2 inhibitor CC-42344 for the treatment of pandemic and seasonal influenza A.

News for Cocrystal Pharma Stock (COCP)